MTOR and renal cell carcinoma: To determine whether the improvements observed with ACA + anti-PD-1 extended to targeted therapies approved for use in metastatic RCC, we combined ACA with the mTOR inhibitor rapamycin or vehicle control (VC) administered in the drinking water (Figure 6A).